A Phase 4 interventional study of Beraprost and Aspirin in Type 2 Diabetes Mellitus, sponsored by Astellas Pharma Inc. Terminated at 6 sites in China. Open to participants aged 50 Years to 75 Years. Per ClinicalTrials.gov, last updated 2016-06-21.
Sponsored by Astellas Pharma Inc · Phase 4, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 15 studies testing aspirin in Diabetes Mellitus, Type 2 — 1 open to participants now, 4 under way, none of them phase 3. Aspirin · Diabetes Mellitus, Type 2.
Among the 15 studies testing aspirin in Diabetes Mellitus, Type 2, this one is the 6th largest by enrollment, is one of 3 that started in 2010, is one of 9 in phase 4, and was the 11th registered.
10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.
Browse Diabetes Mellitus, Type 2 studies →1 of the 15 studies testing aspirin in Diabetes Mellitus, Type 2 is open now, in 1 country. Recruiting first, the newest first:
Montreal Heart Institute · Sites in Canada
Ages 18+
By country, each count listing its studies:
Aspirin: first FDA approval 1950 (PERCODAN), first EMA approval 2010. What it is approved for, and how studies give it, is on its page →
Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.
This study: 50 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
15 studies; the count open now beside each. This study's row is marked.
First in 2002; this study’s year is marked. 3 started in 2010.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 190 is above the median of 80 across 8,361 interventional studies indexed under Diabetes Mellitus, Type 2.
Median enrollment 80 across the 15 interventional studies. Of the 9 that completed or were terminated, 2 (22%) have results posted.
This tab as a report to print or save as PDF → With an account.
1 of 15 have an industry lead sponsor. The 10 most frequent:
Astellas Pharma Inc is the lead sponsor of 525 studies on the registry; 4 are open to participants now.
Of its 28 completed or terminated interventional studies of FDA-regulated products, 19 (68%) have results posted.
35 studies in Diabetes Mellitus, Type 2 by Astellas Pharma Inc: none open now, none under way, none of them phase 3. Of 35 finished, 1 (3%) have results posted.
Among the 35 studies in Diabetes Mellitus, Type 2 by Astellas Pharma Inc, this one is the 8th largest by enrollment of the 32 interventional ones that give a count, is one of 12 that started in 2010, is one of 5 in phase 4, and was the 32nd registered.
Astellas Pharma Inc’s Diabetes Mellitus, Type 2 studies by the year they started, since 2007.
1 of the studies testing aspirin in Diabetes Mellitus, Type 2 that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05702463Montreal Heart InstituteAssessing Pharmacokinetics and Pharmacodynamics of Daily Enteric-coated Aspirin in Patients With StablE Diabetes II | 2027-06-01 |
Add it to your calendar (.ics) → With an account.
Among the 15 studies testing aspirin in Diabetes Mellitus, Type 2, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Astellas Pharma Inc’s 35 in Diabetes Mellitus, Type 2:
This tab as a report to print or save as PDF → With an account.
The objective was to evaluate the efficacy and safety of combination of beraprost and aspirin for prevention of arteriosclerosis progress in type 2 diabetes mellitus patients.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Oral
Drug: Beraprost · Drug: Aspirin
Oral
Drug: Aspirin
Change from baseline in carotid intima-media thickness
Time frame: Baseline to Year 3
Incidence and severity of treatment-emergent adverse events
Time frame: Up to 3 years
Safety assessed by vital signs: body temperature
Time frame: Up to 3 years
Safety assessed by vital signs: pulse rate
Time frame: Up to 3 years
Safety assessed by vital signs: respiratory rate
Time frame: Up to 3 years
Safety assessed by vital signs: blood pressure (systolic blood pressure and diastolic blood pressure)
Time frame: Up to 3 years
Number of participants with abnormal laboratory values and/or adverse events related to treatment
Time frame: Up to 3 years
Death rate
Time frame: Up to 3 years
Incidence of any vascular event
Vascular events include sudden death, death caused by the vascular event, non-fatal coronary hear disease (CHD), non-fatal cerebrovascular diseases, and non-fatal aorta and peripheral artery disease (PAD)
Time frame: Baseline to Year 3
Change from baseline in Ankle-brachial index
Time frame: Baseline to Year 3
Change from baseline in Pulse wave velocity
Time frame: Baseline to Year 3
Change from baseline in Oxidative stress indices
Oxidative stress indices: superoxide dismutase and nitrotyrosine
Time frame: Baseline to Year 3
Change from baseline in value of VCAM-1
VCMA-1: vascular cell adhesion molecule
Time frame: Baseline to Year 3
Change from baseline in value of TNF-α
TNF: tumor necrosis factor
Time frame: Baseline to Year 3
Plan to share: Undecided
No publications or documents are linked to this record.
The record gives a start of Jul 2010, a primary completion of Jan 2013 and a completion of Jan 2013. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in May 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Aspirin